Loading...
The ARMYDA study showed that pretreatment with atorvastatin reduces the risk for MI during percutaneous coronary intervention in patients with stable angina. Can a similar result be achieved in patients with acute coronary syndromes? To find out, the same investigators randomly assigned 171 ACS patients in Italy to receive either high-dose atorvastatin (80 mg a mean of 12 hours before, plus 40 mg 2 hours before) or placebo before early PCI (<48 hours). All patients received aspirin, clopidogrel, and heparin; glycoprotein IIb/IIIa inhibitors were used at the physician’s discretion. All patients received atorvastatin (40 mg/day) through the 30-day endpoint.
Baseline characteristics, including angiographic lesion characteristics and procedure …